WO2022243907 - FORMULATIONS OF 3-((3-(4-(2-(ISOBUTYLSULFONYL)PHENOXY)-3-(TRIFLUOROMETHYL)PHENYL)-1,2,4-OXADIAZOL-5-YL)METHYL)-5,5-DIMETHYL-1-(2-MORPHOLINOETHYL)IMIDAZOLIDINE-2,4-DIONE
National phase entry:
Publication Number
WO/2022/243907
Publication Date
24.11.2022
International Application No.
PCT/IB2022/054640
International Filing Date
18.05.2022
Title **
[English]
FORMULATIONS OF 3-((3-(4-(2-(ISOBUTYLSULFONYL)PHENOXY)-3-(TRIFLUOROMETHYL)PHENYL)-1,2,4-OXADIAZOL-5-YL)METHYL)-5,5-DIMETHYL-1-(2-MORPHOLINOETHYL)IMIDAZOLIDINE-2,4-DIONE
[French]
FORMULATIONS DE 3-((3-(4-(2-(ISOBUTYLSULFONYL)PHÉNOXY)-3-(TRIFLUOROMÉTHYL)PHÉNYL)-1,2,4-OXADIAZOL-5-YL)MÉTHYL)-5,5-DIMÉTHYL-1-(2-MORPHOLINOÉTHYL)IMIDAZOLIDINE-2,4-DIONE
Applicants **
NOVARTIS AG
Lichtstrasse 35
4056 Basel, CH
Inventors
RIDRUEJO, Nuria Jimenez
Novartis Pharmaceuticals Corporation
6201 South Freeway
Fort Worth, Texas 76134, US
LAKSHMAN, Jay Parthiban
Novartis Pharmaceuticals Corporation
One Health Plaza
East Hanover, New Jersey 07936, US
RAYABANDLA, Sunil Kumar Mandala
Novartis Pharmaceuticals Corporation
6201 South Freeway
Fort Worth, Texas 76134, US
TOWLER, Christopher Stephen
Novartis Institutes for BioMedical Research, Inc.
250 Massachusetts Avenue
Cambridge, Massachusetts 02139, US
FAN, Yi
Novartis Institutes for BioMedical Research, Inc.
10675 John Jay Hopkins Drive
San Diego, California 92121, US
HARDY, Declan
Novartis Institutes for BioMedical Research, Inc.
250 Massachusetts Avenue
Cambridge, Massachusetts 02139, US
HUANG, Zhihong
Novartis Institutes for BioMedical Research, Inc.
10675 John Jay Hopkins Drive
San Diego, California 92121, US
LOREN, Jon Christopher
Novartis Institutes for BioMedical Research, Inc.
10675 John Jay Hopkins Drive
San Diego, California 92121, US
MOLTENI, Valentina
Novartis Institutes for BioMedical Research, Inc.
10675 John Jay Hopkins Drive
San Diego, California 92121, US
SHAW, Duncan
Novartis Institutes for BioMedical Research, Inc.
250 Massachusetts Avenue
Cambridge, Massachusetts 02139, US
SMITH, Jeffrey
Novartis Institutes for BioMedical Research, Inc.
10675 John Jay Hopkins Drive
San Diego, California 92121, US
Priority Data
63/191,293
20.05.2021
US
63/269,675
21.03.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1885 | |
| EPO | Filing, Examination | 9238 | |
| Japan | Filing | 589 | |
| South Korea | Filing | 607 | |
| USA | Filing, Examination | 6710 |
Total: 19029 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Formulations of 3-((3-(4-(2-(isobutylsulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-5,5-dimethyl-1-(2-morpholinoethyl)imidazolidine-2,4-dione and pharmaceutically acceptable salts thereof, processes for their production, and uses thereof, including in the treatment of ocular diseases and disorders such as dry eye disease and Meibomian gland dysfunction (MGD).[French]
Formulations de 3-((3-(4-(2-(isobutylsulfonyl)phénoxy)-3-(trifluorométhyl)phényl)-1,2,4-oxadiazol-5-yl)méthyl)-5,5-diméthyl-1-(2-morpholinoéthyl)imidazolidine-2,4-dione et de sels de qualité pharmaceutique de celle-ci, procédés pour leur production, et leurs utilisations, y compris dans le traitement de maladies et de troubles oculaires tels que le syndrome de l'œil sec 5 et un dysfonctionnement des glandes de Meibomius.